NHS England improves offer to Vertex over CF drugs
NHS officials in England have made an improved two-year pricing deal to Vertex Pharmaceuticals in a bid to give patients access to cystic fibrosis (CF) medicines.
John Stewart, national director of specialised commissioning for NHS England outlined sketchy details of the new proposal to Dr Sarah Wollaston MP, chair of the influential Commons Health Committee.
Read more...